Michiel Van De Sande, MD, PhD, Leiden University Medical Center, Leiden, Netherlands, comments on the role of artificial intelligence (AI) in the management of sarcoma. Compared to currently used statistical models, AI is useful in assessing X-rays and pathology tests, where there are large data sets. AI can additionally be deployed to assess infection rates and the risk of disease progression in patients. This interview took place at the ESMO Sarcoma and Rare Cancers Congress 2023 in Lugano, Switzerland.
These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.